top of page
Doctor Treating Patient

IMVT-1402-2401
Clinical Study

A clinical study by Immunovant Sciences evaluating IMVT-1402, an investigational therapy designed to reduce disease-driving antibodies in people with chronic autoimmune conditions such as CIDP. The trial aims to assess its safety, tolerability, and ability to improve long-term disease control—offering hope for more sustained symptom relief and a better quality of life for patients who have not responded well to existing treatments. 

​

To qualify, participants generally must:

​​​​

  • Age: 18 years or older

​

  • Have a confirmed diagnosis of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

​

  • Meet recognized CIDP diagnostic standards (EAN/PNS guidelines), including:

    • Clinical diagnosis of typical CIDP or variants (multifocal or motor CIDP)

    • Electrodiagnostic (nerve test) confirmation supporting CIDP

​

  • Be on stable treatment for at least ~3 months, such as:

    • IVIG or SCIG (immunoglobulin therapy), and/or

    • Systemic corticosteroids (stable dose)

bottom of page